Innovations in linker design are focused on multiple issues ranging from serum stability to mechanism of release to drug to antibody ratio (DAR). As linkers become increasingly sophisticated, more …

Dec 1, 2021 · Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, …

Jul 1, 2025 · Antibody-drug conjugates (ADCs) 1, 2 are innovative therapeutic agents that combine monoclonal antibodies with cytotoxic drugs via chemical linkers 3, enabling precise and targeted …

May 27, 2025 · Linker tethering payload to antibody is vital for ADC. This review provides an overview of linkers of 17 approved ADCs and recent innovations in linker design, focusing on drug release …

Sep 30, 2024 · Antibody-drug conjugates (ADCs) are “biological bullets” that combine cytotoxic drugs (payloads) with antibodies through “linkers.” ADCs consist of five key elements: target, antibody, …

An antibody is linked to a small molecule via a covalent tether. A linker may be a small part of an antibody-drug conjugate, but drugmakers are finding that linker chemistry is important.

The antibody can be viewed as the “navigation system,” the payload as the “warhead.” Central to this triad is the linker—a molecular scaffold that not only tethers the payload to the antibody but also …

Jun 23, 2021 · The development of antibody-drug conjugates (ADCs) has significantly been advanced in the past decade given the improvement of payloads, linkers and conjugation methods. In particular, …

Aug 2, 2025 · Inspired by the "magic bullet" concept proposed over a century ago, antibody-drug conjugates (ADCs) are developed to enhance cancer therapy by linking monoclonal antibodies to a …

NJ Bio, Inc., offers the following payload-linker services: Payload Synthesis and Optimization Synthesis of linkers with compatible conjugation chemistry and suitable release mechanisms Process …